A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Summary

The main aim of this study is to learn how the body of a child or teenager with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) processes vedolizumab (pharmacokinetics) given just under the skin subcutaneously (SC). The participants will be treated with vedolizumab for up to 34 weeks. During the study, participants will visit their study clinic several times.

Timeline

Start

2025-01-22

Primary completion

2027-11-15

Completion

2027-11-15

Drugs

Indications